Related Experiment Video

Updated: Jul 12, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Potential role of multi-targeted tyrosine kinase inhibitors in non-small-cell lung cancer

G V Scagliotti1

  • 1Department of Clinical and Biological Sciences, University of Torino, Turin, Italy. giorgio.scagliotti@unito.it

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 21, 2007
PubMed

Insights

Targeted therapies show promise for non-small cell lung cancer (NSCLC). Multi-targeted agents may offer greater efficacy than single-target drugs by inhibiting multiple cancer pathways, potentially leading to synergistic antitumor effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy offers limited treatment outcomes for metastatic non-small cell lung cancer (NSCLC).
  • Novel targeted agents are being evaluated in clinical trials for NSCLC.
  • Current targeted therapies like erlotinib and bevacizumab show modest but improved clinical outcomes by targeting single molecules.

Purpose of the Study:

  • To evaluate the potential of multi-targeted therapeutic agents in treating NSCLC.
  • To explore whether multi-targeted agents can overcome limitations of single-target therapies.
  • To investigate the synergistic antitumour effects of multi-targeted agents in NSCLC.

Main Methods:

  • Review of clinical trials evaluating targeted agents for NSCLC.
  • Analysis of preclinical studies on multi-targeted agents (e.g., sunitinib, sorafenib).
  • Examination of molecular pathways implicated in NSCLC heterogeneity and resistance.

Main Results:

  • Single-target agents like erlotinib and bevacizumab have demonstrated improved outcomes in NSCLC.
  • NSCLC's heterogeneity suggests multi-targeted agents may be more effective.
  • Preclinical data indicate multi-targeted agents may inhibit multiple pathways, leading to synergistic antitumour effects.

Conclusions:

  • Multi-targeted agents hold promise for improved NSCLC treatment outcomes.
  • Inhibition of multiple aberrant molecular pathways may be key to overcoming treatment resistance.
  • Further clinical evaluation of multi-targeted agents is warranted for NSCLC.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...